The University of Texas Health Science Center, Houston
This is a 7-year prospective single-center registry study to assess the safety and efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the treatment of pancreatic lesions.
Inclusion Criteria: * Diagnosis of any pancreatic pre-malignant lesion and/or pancreatic malignancy * Patients already undergoing EUS-RFA for treatment of pancreatic lesions clinically Exclusion Criteria: * Patients with co-existing malignancies of other organs (or a prior history of such) * Patients unable to provide informed consent * Patients unable to complete follow-up
EUS-guided Radiofrequency Ablation (RFA) consists of the application of alternating current with a frequency of 350-500 kHz (coincidentally the frequency range of radio broadcasts as well) to the target tissue via a special electrode located at the tip of the endoscope.
Arctuva estimate
Verify or correct the compensation shown for this listing.